We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Possible Bio-Marker for Type 2 Diabetes Identified

By Biotechdaily staff writers
Posted on 12 Jul 2006
Researchers have found that retinol-binding protein 4 (RBP4), a molecule that transports vitamin A in the blood, might be an effective marker for predicting the likelihood of developing non-insulin-dependent diabetes (type 2) diabetes.

Type 2 diabetes, also called adult-onset diabetes, results from the inability of the cells in the body to respond to insulin. More...
About 90% of diabetics have this form, which is more prevalent in non-whites and usually occurs after age 40. Although the cause is not completely understood, there is a genetic factor and 90% of those affected are obese.

Investigators at Harvard Medical School (Boston, MA, USA) exploited previous findings that RBP4, a protein secreted from adipose tissue, was linked to insulin resistance in mice. In the current study they measured serum RBP4 levels, insulin resistance, and components of the metabolic syndrome in three groups of subjects (from the United States, Sweden, and Germany). Individuals in one set of subjects were obese, demonstrated impaired glucose tolerance, or were ill with type 2 diabetes. Individuals in a second group had normal body weight and normal blood glucose, but had a strong family history of type 2 diabetes.

Results published in the June 15, 2006, issue of The New England Journal of Medicine, revealed that serum RBP4 levels correlated with the magnitude of insulin resistance in subjects with obesity, impaired glucose tolerance, or type 2 diabetes and in non-obese, non-diabetic subjects with a strong family history of type 2 diabetes. Elevated serum RBP4 was associated with components of the metabolic syndrome, including increased body-mass index, waist-to-hip ratio, serum triglyceride levels, systolic blood pressure, and decreased high-density lipoprotein cholesterol levels.

Some patients were assigned an exercise regimen to lower their weight and degree of insulin resistance. Only those showing an improvement in insulin resistance experienced a reduction in serum RBP4 levels.

"Collectively, these findings tell us that RBP4 is a useful marker for therapeutic improvement and that this protein could play a causal role in insulin resistance in humans, just as our lab previously showed in mice,” said senior author Dr. Barbara Kahn, professor of endocrinology at Harvard Medical School. "Furthermore, because RBP4 levels consistently corresponded with insulin resistance--even among lean subjects whose genetic risk for the development of diabetes might otherwise be overlooked--this protein could be an important marker for type 2 diabetes among the general population. Being able to determine diabetes risk well before the onset of symptoms could provide an important opportunity for patients to take preventive measures.”



Related Links:
Harvard Medical School

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Pipette Calibration System
Artel PCS®
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.